Related Experiment Video
Updated: Aug 16, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Identification and Treatment of SMARCA4 Deficient Poorly Differentiated Gastric Carcinoma
Vipul Bhat1, Manisha Koneru1, Kristen Knapp2
1Department of Medical School, Cooper Medical School of Rowan University, Camden, NJ, USA.
Abstract:
Loss of expression of the SMARCA4 gene, a subunit of the SWI/SNF complex, has been historically associated with thoracic sarcomas. This loss of expression is extremely rare in gastric cancers, and its role in gastrointestinal tract carcinomas has not been fully elucidated. We report a case of a 73-year-old male with poorly differentiated, SMARCA4-deficient gastric cancer, showing that this immunophenotype is not limited to thoracic sarcomas or advanced-stage tumors. These tumors are often resistant to conventional FLOT chemotherapy and have poor prognoses, necessitating the need for early identification and alternative therapeutic approaches. New therapies such as EZH2 inhibitors and etoposide should be considered in cases where standard treatments are ineffective.
Insights
SMARCA4 deficiency, typically seen in thoracic sarcomas, can occur in gastric cancer. This rare finding in gastric tumors indicates poor prognosis and resistance to chemotherapy, necessitating new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Loss of SMARCA4 gene expression is a known hallmark of thoracic sarcomas.
- The role of SMARCA4 deficiency in gastrointestinal tract carcinomas, particularly gastric cancer, remains largely unelucidated.
- Gastric cancers with SMARCA4 deficiency are rare and their clinical significance is not well understood.
Observation:
- A case report of a 73-year-old male with poorly differentiated gastric cancer exhibiting SMARCA4 deficiency.
- This immunophenotype was observed in a non-thoracic sarcoma and a non-advanced stage tumor.
- The gastric cancer presented with resistance to standard FLOT chemotherapy.
Findings:
- SMARCA4 deficiency is not exclusive to thoracic sarcomas.
- SMARCA4-deficient gastric cancer can occur in earlier stages and presents a poor prognosis.
- These tumors demonstrate resistance to conventional chemotherapy regimens like FLOT.
Implications:
- Early identification of SMARCA4-deficient gastric cancer is crucial for patient management.
- Alternative therapeutic strategies are needed for patients with this rare tumor subtype.
- Novel therapies, including EZH2 inhibitors and etoposide, show potential for treating SMARCA4-deficient gastric cancers.
More Related Videos
08:12Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
03:32Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024